# Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

> **NCT02161731** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Evacetrapib
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02161731
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161731, "Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02161731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*